2011 - CTS-IXA

SOTA 2- Immunomodulation and Cell Based Strategies for Tolerance Induction (Cell Track)

11.155 - Chimerism

Presenter: Suzanne, Ildstad, Louisville, United States
Authors: Suzanne Ildstad



Suzanne T. Ildstad

Louisville, KY, United States

Solid organ, vascularized composite tissue, and islet transplantation currently require nonspecific immunosuppressive agents indefinitely for graft maintenance. These agents have significant toxicities, including nephrotoxicity, opportunistic infections, increased rate of malignancy, diabetes, and hypertension. Approaches to induce tolerance are therefore being pursued. It has been known for over 50 years that bone marrow chimerism induces tolerance to transplanted organs, cells, and tissues. The chimerism assoiciated with tolerance is robust and is to date the only approach that has translated successfully form mice to nonhuman primates to humans. However, the requirement for close HLA matching and toxicity of ablative bone marrow transplantation has limited the widespread application of this approach to date. This presentation will review the current status of chimerism and tolerance initiatives underway and update outcomes in an active clinical program addressing kidney/hematopoietic stem cell transplant (HSCT) recipients, metachromatic leukodystrophy, and sickle cell disease transplant in which we have safely established durable chimerism in highly mismatched donor/recipient pairs. The induction of donor-specific tolerance through durable chimerism in mismatched recipients while avoiding graft-versus-host disease (GVHD) would impact organ and tissue recipients as well as for individuals with hemoglobinopathies, inherited metabolic disorders, and autoimmune disorders.

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory


The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7